Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial data
Biotech
Sanofi crosses Sjögren's off $5B drug's hit list after phase 2
Sanofi axed Sjögren’s from the list of targeted indications for frexalimab—and reported a phase 3 flop for one of its tarnished former top prospects.
Nick Paul Taylor
Apr 25, 2024 2:35am
Sanofi nails phase 3 LUNA landing, sparking race to regulators
Apr 23, 2024 2:23am
AbbVie-bound Cerevel reports phase 3 Parkinson's victory
Apr 18, 2024 8:34am
Pulmocide exits OPERA with evidence of antifungal efficacy
Apr 15, 2024 9:41am
Neumora schizophrenia drug on FDA hold over rabbit convulsions
Apr 15, 2024 9:00am
MaaT posts 18-month data showing 'clear OS advantage' in aGvHD
Apr 15, 2024 7:05am